FDA Approves SUNLENCA — Gilead Sciences, Inc.

# FDA Approves Gilead Sciences' SUNLENCA (Lenacapavir Sodium) for HIV Treatment Gilead Sciences, Inc. received FDA approval for SUNLENCA (lenacapavir sodium), an oral HIV capsid inhibitor representing a novel mechanism of action that could reshape treatment options for HIV patients and expand Gilead's antiviral portfolio. The approval of this first-in-class drug positions Gilead to capture significant market share in the competitive HIV therapeutic space, potentially driving revenue growth and strengthening its position as a leader in infectious disease treatments.